Our CME author Aaron Loyd nicely traced the big events of the ending year with his wrap-up “2007 Year in Review,” which starts on page 44. And what a year it was with many positive advances made in the field of dermatology. Here are a few, but you’ll find many more in this month’s CME article.
The Main Events in Dermatology
It’s on the news, it’s in the newspapers, and it’s quite possibly in your practice as well. In 2007 and still ongoing is the growing community health threat of MRSA. Dr. Loyd highlights the need to focus on diagnosis and early treatment, starting with excision and drainage of suspicious lesions.
On the acne front, the iPLEDGE program continued to work out its kinks to maximize effectiveness for appropriate candidates and minimize risk to others. Exciting new acne therapies included a higher concentration of topical adapalene, non-microbicidal tetracycline derivatives and drospirenone-containing oral contraceptives (Yaz).
For those with recalcitrant atopic dermatitis, cyclosporine was the big news, while in psoriasis, trials of the biologic efalizumab in palmoplantar psoriasis showed one-third of patients achieving near or full clearance with the therapy.
For autoimmune disorders, rituximab’s “wide-reaching applications” included pemphigus vulgaris, dermatomyositis, systemic lupus erythematosus and rheumatoid arthritis.
Cosmetic dermatology innovations included a longer lasting hyaluronic acid filler, Juvéderm, as well as other relevant highlights.
And pay for performance has moved beyond theory to practice for dermatologists whose compliance with physician quality reporting initiatives now requires reporting of adequate history, exam and counseling for patients with a history of malignant melanoma.
Round Up of Content
Did you miss an article, column or supplement this year? Or, maybe you want to quickly cross-reference one of your favorite authors. Turn to page 59 for our 2007 Article & Author Index, an easy reference guide to our 2007 published material.
Larisa Hubbs
Executive Editor
lhubbs@hmpcommunications.com
Our CME author Aaron Loyd nicely traced the big events of the ending year with his wrap-up “2007 Year in Review,” which starts on page 44. And what a year it was with many positive advances made in the field of dermatology. Here are a few, but you’ll find many more in this month’s CME article.
The Main Events in Dermatology
It’s on the news, it’s in the newspapers, and it’s quite possibly in your practice as well. In 2007 and still ongoing is the growing community health threat of MRSA. Dr. Loyd highlights the need to focus on diagnosis and early treatment, starting with excision and drainage of suspicious lesions.
On the acne front, the iPLEDGE program continued to work out its kinks to maximize effectiveness for appropriate candidates and minimize risk to others. Exciting new acne therapies included a higher concentration of topical adapalene, non-microbicidal tetracycline derivatives and drospirenone-containing oral contraceptives (Yaz).
For those with recalcitrant atopic dermatitis, cyclosporine was the big news, while in psoriasis, trials of the biologic efalizumab in palmoplantar psoriasis showed one-third of patients achieving near or full clearance with the therapy.
For autoimmune disorders, rituximab’s “wide-reaching applications” included pemphigus vulgaris, dermatomyositis, systemic lupus erythematosus and rheumatoid arthritis.
Cosmetic dermatology innovations included a longer lasting hyaluronic acid filler, Juvéderm, as well as other relevant highlights.
And pay for performance has moved beyond theory to practice for dermatologists whose compliance with physician quality reporting initiatives now requires reporting of adequate history, exam and counseling for patients with a history of malignant melanoma.
Round Up of Content
Did you miss an article, column or supplement this year? Or, maybe you want to quickly cross-reference one of your favorite authors. Turn to page 59 for our 2007 Article & Author Index, an easy reference guide to our 2007 published material.
Larisa Hubbs
Executive Editor
lhubbs@hmpcommunications.com
Our CME author Aaron Loyd nicely traced the big events of the ending year with his wrap-up “2007 Year in Review,” which starts on page 44. And what a year it was with many positive advances made in the field of dermatology. Here are a few, but you’ll find many more in this month’s CME article.
The Main Events in Dermatology
It’s on the news, it’s in the newspapers, and it’s quite possibly in your practice as well. In 2007 and still ongoing is the growing community health threat of MRSA. Dr. Loyd highlights the need to focus on diagnosis and early treatment, starting with excision and drainage of suspicious lesions.
On the acne front, the iPLEDGE program continued to work out its kinks to maximize effectiveness for appropriate candidates and minimize risk to others. Exciting new acne therapies included a higher concentration of topical adapalene, non-microbicidal tetracycline derivatives and drospirenone-containing oral contraceptives (Yaz).
For those with recalcitrant atopic dermatitis, cyclosporine was the big news, while in psoriasis, trials of the biologic efalizumab in palmoplantar psoriasis showed one-third of patients achieving near or full clearance with the therapy.
For autoimmune disorders, rituximab’s “wide-reaching applications” included pemphigus vulgaris, dermatomyositis, systemic lupus erythematosus and rheumatoid arthritis.
Cosmetic dermatology innovations included a longer lasting hyaluronic acid filler, Juvéderm, as well as other relevant highlights.
And pay for performance has moved beyond theory to practice for dermatologists whose compliance with physician quality reporting initiatives now requires reporting of adequate history, exam and counseling for patients with a history of malignant melanoma.
Round Up of Content
Did you miss an article, column or supplement this year? Or, maybe you want to quickly cross-reference one of your favorite authors. Turn to page 59 for our 2007 Article & Author Index, an easy reference guide to our 2007 published material.
Larisa Hubbs
Executive Editor
lhubbs@hmpcommunications.com
